GH Research Reports Third Quarter Financial Results and Provides Business Updates
09 nov. 2023 16h45 HE
|
GH Research PLC
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs
07 nov. 2023 12h11 HE
|
TrustPoint Hospital
MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are...
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
06 nov. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two...
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
03 oct. 2023 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
29 sept. 2023 16h45 HE
|
GH Research PLC
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
23 août 2023 07h00 HE
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
08 août 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3...
The Future of Global Mental Health Management Research Report 2023: Complementing Prescription Therapies with AI/ML/VR for Better Outcomes to Become More Prominent
20 juil. 2023 05h38 HE
|
Research and Markets
Dublin, July 20, 2023 (GLOBE NEWSWIRE) -- The "The Future of Mental Health Management" report has been added to ResearchAndMarkets.com's offering. This report identifies the challenges, drivers,...
Circular Genomics Announces Two Significant Steps Forward in Linking CircRNA to the Detection, Therapy Selection and Monitoring of Depressive Conditions
11 juil. 2023 14h32 HE
|
Circular Genomics
Albuquerque, NM, July 11, 2023 (GLOBE NEWSWIRE) -- Circular Genomics, the global leader in the use of circular RNA (circRNA) biomarkers for precision psychiatry, today announced the results of a new...